1620 Investment Advisors Inc. Buys 48 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

1620 Investment Advisors Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 671 shares of the medical research company’s stock after acquiring an additional 48 shares during the period. 1620 Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $349,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. One Charles Private Wealth Services LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company’s stock worth $260,000 after purchasing an additional 20 shares during the period. Lee Danner & Bass Inc. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $60,000. Ballast Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 10.5% in the 4th quarter. Ballast Advisors LLC now owns 1,923 shares of the medical research company’s stock worth $1,000,000 after purchasing an additional 182 shares during the period. Whittier Trust Co. of Nevada Inc. increased its holdings in Thermo Fisher Scientific by 4.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 40,587 shares of the medical research company’s stock worth $21,114,000 after acquiring an additional 1,785 shares in the last quarter. Finally, Holderness Investments Co. increased its holdings in Thermo Fisher Scientific by 1.7% in the 4th quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company’s stock worth $664,000 after acquiring an additional 21 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock worth $13,106,062 in the last ninety days. 0.34% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Scotiabank increased their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a report on Monday, February 3rd. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a report on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Citigroup cut their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Raymond James reissued an “outperform” rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $518.58 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The firm has a 50 day moving average of $546.65 and a 200 day moving average of $556.94. The company has a market capitalization of $195.64 billion, a price-to-earnings ratio of 31.37, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.